For Admin

  • HOME
  • BUSINESS
  • TECHNOLOGY
  • APPLICATION
  • PARTNERING
  • NEWS
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012〜
  • CONTACT

Shin Nippon Biomedical Laboratories, Ltd. Translational Research Business

Japanese

A Leading Company in Nasal Drug Delivery

  • HOME
  • BUSINESS
  • TECHNOLOGY
    • Platform Technology
    • Special Analysis
    • Publication
  • APPLICATION
    • Absorption
    • Vaccination
    • Nose-to-Brain
  • PARTNERING
  • NEWS
  • CONTACT
  • PRIVACY POLICY

Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Widely Applicable Technology

For Absorption
For Vaccination
For Nose-to-Brain

Expertise in Nasal Delivery

3D Nasal Cast Model

preview
next

News

2022

November 24, 2022

SNBL’s Comments on Results from Clinical Phase 3 Studies of STS101, an Investigational Migraine Drug Candidate, Announced by Satsuma Pharmaceuticals, Inc.

November 14, 2022

Satsuma Pharmaceuticals Announces Topline Results from the STS101 SUMMIT Phase 3 Efficacy Trial for the Acute Treatment of Migraine

September 21, 2022

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial

2022|2021|2020|2019|2018|2016|2015|2014|2013|2012〜

BACK
  • HOME
  • BUSINESS
  • TECHNOLOGY
  • APPLICATION
  • PARTNERING
  • NEWS
  • CONTACT
  • PRIVACY POLICY
Cookie Policy | Sitemap
© Shin Nippon Biomedical Laboratories, Ltd. All Rights Reserved.
Log out | Edit